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regulating the expression of myelin basic protein
after cerebral ischemia injury in rats
Li Zhao, Yunliang Guo*, Xiaojun Ji and Meizeng ZhangAbstract
Background: To explore the neuroprotective effect and optimize the therapeutic dose and time window of
picroside II by orthogonal test and the expression of myelin basic protein (MBP) in cerebral ischemic injury in rats.
Bilateral common carotid artery occlusion (BCCAO) was used to establish forebrain ischemia models. The successful
rat models were grouped according to orthogonal experimental design and injected picroside II intraperitoneally
at different ischemic time with different doses. Myelin sheath fast green staining(FGS) and transmission electron
microscopy (TEM) were used to observe nerve fiber myelin; the expression of MBP was tested qualitatively and
quantitatively by immunohistochemical assay (IHC) and Western blot (WB); Reverse transcription polymerase
chain reaction (RT-PCR) was used to detect the transcription level of MBP mRNA.
Results: The protective effect of picroside II was presented by increasing the expression of MBP and decreasing
demyelination after cerebral ischemic injury. The best therapeutic time window and dose was (1) ischemia 2.0 h
with picroside II 10 mg/kg body weight according to the results of FGS, IHC and WB; (2) ischemia 1.5 h with
picroside II 20 mg/kg according to the analysis of RT-PCR.
Conclusion: Given the principle of the longest time window and the lowest therapeutic dose, the optimized
therapeutic dose and time window should be injecting picroside II intraperitoneally with 10-20 mg/kg body
weight at ischemia 1.5-2.0 h in cerebral ischemic injury.
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As an important myelin sheath structural protein in cen-
tral nervous system (CNS)[1], myelin basic protein (MBP)
lies in the serous surface of myelin sheath and closely inte-
grates with the lipids of myelin and beneficial to steady
the structure and function of myelin in CNS [2]. MBP has
the specificity of nervous tissues [3], MBP lossing will lead
to myelination obstacles and its level can reflect the seve-
rity of the damage of CNS and myelin [4], so that sufficient
MBP is important for the function recovery of the CNS [5].
Animal experiments [6] proved that there was a small
amount expression of MBP mRNA in the brain of normal
adult rats, while the MBP mRNA [7] and protein [8]
decreased time-dependently in early stage of cerebral* Correspondence: guoqdsd@163.com
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stated.ischemic injury [9]. However, the expression of MBP
mRNA will rise slightly as the ischemic time exten-
sion, and its expressing level at ischemia 7d was sig-
nificantly higher than that at ischemia 1d. Previous
study reported that acupuncture treatment could increase
MBP expression and promote the regeneration of myelin
[10]. Picroside II, an active ingredient of traditional Chinese
medicine, has many neuroprotective effects of antioxidant,
anti-inflammatory, anti-apoptosis [11,12], however, whether
it could influence the expression levels of MBP or not has
not been reported so far. Recently, we explored the treat-
ment dose and time window of picroside II after cerebral
ischemia reperfusion injury via the neurobehavioral func-
tion of rats, cerebral infarction volume and immunohisto-
chemical staining and proved that injecting picroside II
20 mg/kg body weight intraperitoneally at ischemia 1.5 h
could achieved a ideal therapeutic outcome for cerebral
ischemic injury in rats [13,14]. In consideration of thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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tochemical assay, we attempted to detect the expression
levels of MBP in brain tissue qualitatively and quantita-
tively and observe the change of myelin structure through
a various biological techniques, just to explore the optimal




In control group, myelin showed cord-like, dark green,
closely arranged after fast green staining. After modeling,
myelin showed loose and light-stained, glial cell vacuo-
lated, and myelin gray value (MGV), gray value of myelin
(GVM), relative content of protein (RCP), relative abun-
dance of mRNA (RAM) were lower markedly than those
in control group (t = 13.79-26.13, P < 0.05). While MGV,
GVM, RCP and RAM were significantly higher than those
in model group after treated by picroside II (t = 3.09-3.71,
P < 0.05)( Table 1, Figures 1, 2, 3 and 4). The orthogonal
test results were shown in Table 2. Data listed in the
Table 2 are the mean of three times of orthogonal experi-
ment. Data of I, II, II, IV and SS were the ANOVA results
of MGV, and the ANOVA results of rest indexes were
omitted.
Results analysis
Myelin gray value (MGV) (Figure 1): The effects of dif-
ferent levels of variable factor A (time) on the injury of
myelin showed a significant difference (P < 0.01), while
no significant influence found among factor B (dose)
and factor C (time-dose interaction) (P > 0.05). That is
to say the administration time had significant impact on
the degree of myelin damage after cerebral ischemia, but
the influence of administration dose and time-dose inter-
action was negligible (Table 3). The pairwise comparisons
of data at different levels according to LSD showed that
the administration time between the groups were statis-
tically significant (P < 0.05). The administration dose be-
tween 5 mg(B1) and 10 mg(B2) was statistically significant
(P < 0.05), while the rest groups were of no statistical sig-
nificance (P > 0.05). From the principle of lowest thera-
peutic dose with longest time window, the optimized
composition were A3B2, that is to say the best therapeutic
dose and time window was ischemia 2.0 h with picroside
II 10 mg/kg body weight by intraperitoneally injection.Table 1 The results of MGV, GVM, RCP and RAM (mean ± SD)
Groups n MGV
Control 5 421.674 ± 30.782
Model 5 273.633 ± 17.421#
Treatment 16 × 3 349.043 ± 46.820*
#P < 0.05 vs control group, *P < 0.05 vs model group.Gray value of myelin (GVM)
(Figure 1): There was a significant difference between
the different levels of impact factors A (time window or
ischemic time) on the expression of myelin (P < 0.05),
while no significant probability (P > 0.05) found among
impact factor B (drug dose) and factor C (time-dose
interaction). This indicated the therapeutic time window
(or ischemic time) had significantly influence on the ex-
pression of myelin after cerebral ischemia injury, while
no significant influence existed in different drug doses
and time-dose interactions (Table 4). LSD showed that
different administration time between 1.0 h(A1) and
1.5 h(A2), 1.0 h(A1) and 2.0 h(A3), 1.5 h(A2) and 2.0 h
(A3), 1.5 h(A2) and 2.5 h(A4), 2.0 h(A3) and 2.5 h(A4)
had significant differences (P < 0.05), no significant dif-
ferences found between the rest groups (P > 0.05). There
was no statistical significance (P > 0.05) between groups
on dose. So, the best combination is A3B2 (2.0 h/10 mg),
that is injecting picroside II 10 mg/ kg body weight at
cerebral ischemia 2.0 h.
Ultrastructure of myelin by TEM: In control group, the
structure of myelin sheath was distinct and neat, and the
neural axon was in focus; while unclear and irregular and
the neural axon disappeared in model group; and the
damaged myelin sheath in treatment group recovered sig-
nificantly comparing with model group (Figure 2).
Relative content of protein (RCP) by WB: Quantitative
detection of the expression of MBP showed that differ-
ent intensity of MBP protein expressed in different
groups (Figure 3), and it was significantly higher than
that in model group after treatment. Analysis of variance
showed that the different levels of factor A (time) had sig-
nificant differences on the expression of MBP (P < 0.05),
but no significant differences in factor B (dose) and factor
C (time-dose interaction) (Table 5). LSD indicated that
significant deviations (P < 0.05) were found between 1.0 h
(A1) and 1.5 h(A2), 1.0 h(A1) and 2.0 h(A3), 1.5 h(A2)
and 2.5 h(A4), 2.0 h(A3) and 2.5 h(A4) in therapeutic
time window, but no significant deviations between
the rest therapeutic time levels (P > 0.05). The differ-
ent therapeutic dose levels had no significant differ-
ences (P > 0.05). Synthetically, the best combination is
A3B2 (1.5 h/10 mg), i.e. the best therapeutic time
window and dose of picroside II should be injecting
intraperitoneally with 10 mg/kg body weight at cere-
bral ischemia 2.0 h.GVM RCP RAM
219.591 ± 17.693 0.801 ± 0.074 1.201 ± 0.099
127.102 ± 6.350# 0.286 ± 0.026# 0.427 ± 0.057#
166.263 ± 12.969* 0.612 ± 0.043* 0.662 ± 0.154*
Figure 1 Myelin nerve fibers in parietal white matter of rats, FGS × 400. Normal myelin (A) showed cord-like, dark green, tightly packed,
and cells was red (Red arrow); it showed myelin fibers loose and light-stained, glial cell vacuolation (Black arrow) after modeling (B). In model
group, myelin gray value (MGV) decreased significantly than that in control group (#P < 0.05 vs control group) and increased significantly than
that in model group after treatment (C) (*P < 0.05 vs model group). The expression of MBP in parietal white matter, SABC × 400. In the control
group (D), myelin fibers was arranged closely and tidy. After modeling (E), myelin degeneration release and disordered, positive cells showed
cytoplasmic uneven coloring, and vesicular (Black arrow). The MBP expressed significantly lower in model group (##P < 0.05 vs control group)
and increased significantly and myelin fibers tightly packed in treatment group (F) (**P < 0.05 vs model group).
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expressions of MBP mRNA differed between various
groups, and increased markedly than that in model
group after treatment (Figure 3). The results of ANOVA
showed there was statistically difference in different
levels of factor A (time) on MBP mRNA (P < 0.05), and
no significant difference (P>0.05) found in factor B
(dose) and factor C (time-dose interaction) (Table 6).
LSD showed that a statistically significance (P < 0.05)
between therapeutic time 1.0 h (A1) and 1.5 h (A2),
1.0 h (A1) and 2.0 h (A3), 1.5 h (A2) and 2.0 h (A3),1.5 h (A2) and 2.5 h (A4), 2.0 h (A3) and 2.5 h (A4), but
no statistical difference in the rest levels (P > 0.05) as
well as the therapeutic dose levels (P > 0.05). Conside-
ration of A2B3 combination is the best, so the best treat-
ment time window and dose is 1.5 h, 20 mg/kg.
Discussion
Orthogonal array is an efficient and economical test,
which has the advantage of balancing samples and redu-
cing the test times at the same time, so that each test has
a strong representation [15]. In this study, we applied the
Figure 2 Ultrastructure of myelin nerve fibers in ischemic cortical area of rats, TEM. C: control group; M: model group; T: treatment group.
The myelin sheath (Black arrow) and the neural axon (*) in control group were distinct and neat (A), and unclear or disappeared in model group
(B), and those injuries was alleviated in treatment (C).
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comparison and statistical analyse, to find better treatment
options through the small number of experiments to
achieve the best therapeutic effect.
Myelin basic protein (MBP), including central and per-
ipheral MBP, has the highest content in while matter. As
a kind of basic membrane proteins with no sugar and
lipid, MBP is synthesized by oligodendrocytes in central
nervous system [16]. Only nerve fibers with myelination
can complete its conduction function, so that MBP is an
important structural protein involved in the synthesis of
myelin and plays an important role in nervous system,
such as insulation and fast conduction in nerve fiber
[17,18]. The transcription products of MBP gene in hu-
man and mouse are different. There are at least 5 kinds
of products including 21.5 kD, 18.5 kD, 17a, 17b and 14
kD in mouse brain. However, there are only 4 kinds of
products consisting of 21.5 kD, 20.2 kD, 18.5 kD and
17.3 kD in human brain, of which the 18.5 kD MBP is
the main protein of mature myelin in central nervous
system [19,20]. Normally the concentration of MBP in
cerebrospinal fluid (CSF) is lower than 6.95 mg/L. After
cerebral ischemia, the ischemia and hypoxia of brainFigure 3 The effect of picroside II on the expression of MBP detected
1–16 were the treatment group rats which were treated in different time with
lower than that in control group (C) (#P < 0.05), while markedly increased aftetissue can lead to oligodendrocyte death and demyelin-
ation, so caused MBP flowing into CSF. In addition,
cerebral injury can damage the structure of blood–brain
barrier (BBB) and cause MBP leaked in CSF passing
through BBB into blood. Therefore, determining the
serum level of MBP could partly reflect whether there
was brain injury or not, and MBP level in serum also
become a specific marker protein to judge demyelination
[21-23]. Previous animal experiments showed that the
expression of MBP mRNA and protein reduced in the
early period of cerebral ischemic injury, especially in the
first 24 h, and the content of MBP protein decreased
significantly [24]. Recently, some experiments [4,25,26]
reported that MBP played an important role in the pre-
diction of the severity of brain injury and the prognosis,
and the increased expression of MBP played a role in
the protection of brain [27]. In this experiment, we de-
termined the expression of MBP mRNA and protein to
evaluate the degree of brain injury. The results showed
that after cerebral ischemic injury, the expression of
MBP mRNA and protein significantly decreased; and
LFB staining and TEM showed that myelin fibers syn-
chronous reduced and the damaged-positive cells wereby Western blot. β-action was used as a loading paraqmeter. Line
different doses. In model group (M), the RCP of MBP was observably
r treatment by picroside II (*P < 0.05 vs model group).
Figure 4 The effect of picroside II on the transcription of MBP mRNA detected by RT-PCR. GAPDH was used as a loading parameter.
“m” presented marker. Line 1–16 were the treatment group rats which were treated in different time with different doses. In model group (M),
the RAM of MBP mRNA was significantly decreased than that in control group (C) (## P < 0.05), while it was markedly increased after treatment
(**P < 0.05 vs model group).
Table 2 [L16 (4
5)] orthogonal table and test results
Test no. Rank no. MGV GVM RCP RAM
A B C D E
1 1 1 1 1 1 283.654 127.002 0.373 0.507
2 1 2 2 2 2 297.874 136.098 0.402 0.596
3 1 3 3 3 3 290.544 137.056 0.39 0.531
4 1 4 4 4 4 320.887 146.417 0.777 0.643
5 2 1 2 3 4 342.117 158.028 0.812 0.777
6 2 2 1 4 3 389.432 190.337 0.707 0.885
7 2 3 4 1 2 396.745 184.114 0.734 0.923
8 2 4 3 2 1 379.667 178.013 0.612 0.789
9 3 1 3 4 2 388.798 189.100 0.901 0.702
10 3 2 4 3 1 420.765 207.135 0.912 0.765
11 3 3 1 2 4 400.456 202.007 0.897 0.801
12 3 4 2 1 3 398.567 195.243 0.798 0.723
13 4 1 4 2 3 330.734 161.477 0.417 0.579
14 4 2 3 1 4 341.100 169.549 0.43 0.455
15 4 3 2 4 1 310.967 147.608 0.276 0.476
16 4 4 1 3 2 292.374 131.03 0.352 0.444
SUM 5584.681 2660.214 9.790 10.596
I 1192.959 1345.303 1365.916 1420.066 1395.053
II 1507.961 1449.171 1349.525 1408.731 1375.791
III 1608.586 1398.712 1400.109 1345.800 1409.277
IV 1275.175 1391.495 1469.131 1410.084 1404.560
SS 28388.071 1356.219 2107.471 864.883 164.684
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Table 3 ANOVA of MGV
Source of variation SS Df MS F P
Time window 28388.071 3 9462.690 55.15 0.01
Drug dose 1356.219 3 452.073 2.64 0.14
Time × dose 2107.471 3 702.490 4.09 0.07
Error 1029.568 6 171.595
Table 5 ANOVA of RCP
Source of variation SS Df MS F P
Time window 0.625 3 0.208 12.84 0.01
Drug dose 0.009 3 0.003 0.18 0.91
Time × dose 0.052 3 0.017 1.06 0.43
Error 0.097 6 0.016
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tion of MBP at all levels can be a biological indicator of
brain injury and demyelination.
Picroside II is an active ingredient of Picrorhizae, which
pharmacological functions consist of cleaning heat, drying
humidity, alleviating fever, eliminating dampness, retreat-
ing steam, cooling blood and cholagogue [28]. Li et al.
[29] confirmed that picroside II had antioxidant effect and
could reduce the H2O2-induced injury in PC12 cells to
improve the cell survival [30]. Our research team found
that picroside II could inhibit the expression of inflamma-
tory factors such as Toll-like receptor 4 (TLR4), nuclear
factor κB (NFκB), caspase enzymes-3 (caspase-3), and
tumor necrosis factor α (TNFα) in cerebral ischemic pen-
umbra after middle cerebral artery occlusion and reperfu-
sion, and then inhibit neuronal apoptosis induced by
ischemia [31-35]. This experiment results showed that
comparing with the model group, the myelin nerve fibers
arranged in order, vacuolar cells decreased, the expression
of MBP and the transcription levels of MBP mRNA
increased on different degrees after treatment by picroside
II. These results proved the neuroprotective effect of
picroside II against cerebral ischemic injury from various
aspects and levels. Further time window and therapeutic
dose optimization showed that injecting picroside II
10-20 mg/kg body weight intraperitoneally at ischemia
1.5 h-2.0 h could be achieved a significant effect against
cerebral ischemic injury.Conclusion
Given the principle of lowest therapeutic dose with lon-
gest time window, the optimized therapeutic dose and
time window should be injecting picroside II intraperito-
neally with 10-20 mg/kg body weight at ischemia 1.5-
2.0 h in cerebral ischemic injury in rats.Table 4 ANOVA of GVM
Source of variation SS Df MS F P
Time window 8916.233 3 2972.078 28.77 0.01
Drug dose 638.716 3 212.905 2.06 0.21
Time × dose 560.222 3 186.741 1.81 0.25
Error 619.788 6 103.298Methods
Establishment of animal models and grouping
Total of 200 adult healthy male Wistar rats (weighted
230-250 g, SPF grade) were supplied by the Experiment
Animal Center of Qingdao Drug Inspection Institute
(SCXK (LU) 20100100). This experiment was approved
by the Ethics Committee of Qingdao University Medical
College (QUMC 2011–09). The local legislation for eth-
ics of experiment on animals and guidelines for the care
and use of laboratory animals were followed in all
animal procedures. All animals were acclimatized for 7d
humidity-controlled housing with natural illumination
and allowed to eat and drink freely at room temperature
(23 ± 2°C). Fifteen (5 × 3) rats were randomly selected
for control group, and the rest 185 rats were anesthe-
tized by injecting intraperitoneally 10% chloral hydrate
(3 ml/kg) after fasting for 12 h and fixed in supine pos-
ition to conduct aseptic operation strictly. The bilateral
common carotid arteries were colligated to establish
forebrain ischemic models (BCCAO) [36,37]. The rats of
control group (5 × 3) were operated as the same experi-
mental procedures besides BCCAO. Core body tempe-
rature was keeping with a rectal probe and maintained at
36-37°C using a homeothermic blanket control unit
during and after the surgery operation. Twenty-six rats
un-awakened or died after 2 h of operation were rejected
out, while 159 successful models whose cerebral blood
flow curve (PeriFlux 5000, Sweden) dropped to 30% were
brought into the experiment and were randomly di-
vided into model group (5 × 3 cases) and treatment group
(16 × 3 × 3 case).
Orthogonal experimental design and intervention
The treatment group rats (16 × 3 × 3 case) were sub-
grouped according to the principle of orthogonal experi-
mental design of [L16(4
5)] consisting of two impact factors
with four impact levels. The impact factor A is the the-
rapeutic time widow designed four levels as 1.0 h, 1.5 h,Table 6 ANOVA of RAM
Source of variation SS Df MS F P
Time window 0.316 3 0.105 46.73 0.01
Drug dose 0.005 3 0.002 0.70 0.59
Time × dose 0.026 3 0.009 3.84 0.08
Error 0.014 6 0.002
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therapeutic drug dose which has four levels as following
5 mg/kg, 10 mg/kg, 20 mg/kg and 40 mg/kg body weight.
The orthogonal experimental test was repeated 3 times.
Picroside II (CAS No: 39012-20-9) which the purity
exceed 98% and molecular formula is C23H28O13, sup-
plied by Tianjin Kuiqing Medical Technology Co. Ltd.
According to the weight of rats, corresponding dose of
picroside II powder was taken and diluted into 1 ml
solution by isotonic saline solution and injected intraper-
itoneally according to the corresponding designed doses
at designed time in the orthogonal layout [L16(4
5)]. Rats
in control group and model group were intraperitoneally
injected the same dose saline after cerebral ischemia 2 h.
The brain tissue was took out to evaluate the therapeutic
effect of picroside II after treatment 24 h.
Fast green staining(FGS)
The rats from control group (5 cases), model group (5
cases) and treatment group (16 × 3 cases) were randomly
chosen and anesthetized by injecting intraperitoneally
10% chloral hydrate (3 ml/kg), and perfused by normal
saline 200 ml and fixed by 4% paraformaldehyde solution
200 ml successively via heart. Then the whole brain was
taken out and post-fixed in 4% formaldehyde solution for
2 h and soaked in distilled water for 4 h. After conven-
tional gradient ethanol dehydration, xylene transparent,
paraffin embedding, coronal sections with a thickness of
5 μm were continuously cut forward from the posterior of
optic chiasma by a microtome (Leica CM2027, Germany)
and then adhered on the slices processed with poly-lysine.
The paraffin sections were dewaxed by dimethyl ben-
zene and washed routinely, dyed 1 h in fast green alcohol
solution at 37°C after dealing with 95% alcohol 1 min, and
then washed by 95% alcohol (10 s × 2 times) and distilled
water (15 s × 3 times), putted in 0.3% lithium carbonate to
separate color, re-stained 90s by nuclear fast red after
washing by distilled water (15 s × 3 times), finally washed
by distilled water and conventionally dehydrated by gra-
dient ethanol, cleared by xylene and sealed with neutral
balsam. Normal myelin showed cord-like, dark green,
tightly packed, and cells were red under light microscope.
Five non-overlap visual fields at ischemic area were ran-
domly observed under 400-fold light microscope. Quan-
tity One software was used to analyse the gray value and
took the mean. The change of myelin was presented by
myelin gray value (MGV =MBP gray value – background
gray value).
Transmission electron microscopy (TEM)
Ultrathin sections: Took some fresh brain tissue from
the ischemic area and cut into pieces of 1 mm × 1 mm×
1 mm, fixed with 2.5% glutaraldehyde for 24 h and 1%
osmium tetroxide for 2 h and dehydrated by gradedseries of acetone. Then soaked with the mixture of
acetone and embedding solution (1:1) for 1.5 h and
pure embedding solution overnight at 37°C respect-
ively. The samples were put into the embedding plate
filled with epoxy resin Epon812 to form embedding
blocks eventually. The 50 nm ultrathin sections were
cut by the ultramicrotome (Leica EM UC6, Germany)
and placed on the nets prepared with polyvinyl formal,
stored at 4°C.
TEM: Dripped a drop of 3% uranyl acetate-alcohol sat-
urated solution (pH = 3.5) in a petri dish, covered the
nets of ultrathin sections to contact with the dye liquor
to stain for 30 min, and rinsed with double-distilled
water for 10 min × 3 times to suck up water. Then, cov-
ered the nets of ultrathin sections to a drop of 6% lead
citrate dye liquor (pH = 12) in another petri dish to stain
for 5 min, rinsed with non-carbon dioxide double-distilled
water for 10 min × 3 times, dried at room temperature.
The ultrastructure of myelin was observed under TEM
(JEM-1200EX, Japan).
Immunohistochemical (IHC) assay
Paraffin sections prepared as above were dewaxed and
washed routinely, operated by the specification of SABC
kit, developed by DAB chromogenic reagent kit and re-
stained by hematoxylin (all kits were provided by Wuhan
Boster Biotech Co. Ltd). Under light microscope myelin
showed claybank streak and positive cells’ cytoplasm
presented uneven coloring, vacuolization in cells. Nega-
tive control slices were dyed with 0.01 mol/L PBS in-
stead of rabbit anti-rat MBP primary antibody and no
positive reaction appeared. Five non-overlap visual fields
randomly at ischemic area were chose under 400-fold
light microscope. The gray value was analysed by the
software of Quantity One and last took the mean.
The expressing intensity of MBP was presented by
gray value of myelin (GVM =MBP gray value – back-
ground gray value).
Western blot (WB)
Extraction of total protein: After treatment 24 h, we ran-
domly chose 5 rats from control group, 5 from model
group and (16 × 3) from treatment group to perfuse
from heart with normal saline 200 ml following anesthe-
tizing by 10% chloral hydrate. Took 200 mg ischemic
brain tissue and put it into 1.5 ml EP tubes, added cell
lysis buffer as the proportion of 1:4 (No. P0013, Biyuntian
Biotech Co. Ltd., China), then grinded fully and homoge-
nized by ultrasonic wave at −4°C ice bath, and collected
the supernatant in another EP tube after centrifuging with
10,949 g for 10 min at 4°C (Eppendorf 5801, Germany).
The BCA-100 protein quantitative kit (Shenneng Biotech.
Co. Ltd., China) was used to determine the protein
content, then stored at −20°C.
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by sodium dodecyl sulfate polyacrylamide gel electropho-
resis (12% separating gel on 75 V and 5% concentrated gel
on 120 V successively) and transferred onto a polyvi-
nylidene difluoride membranes (40 min with 360 mA).
Phosphate buffered saline with Tween-10 (PBST) was
used to wash the gel films 5 min by 3 times, then the films
were added rabbit anti-rat MBP primary antibodies (1:450,
Abcam Company, Ab40390) to incubate 2 h and washed
by PBST for 10 min by 3 times, then incubated 1 h
in horseradish peroxidase goat anti-rabbit antibodies
(1:10000, Beijing Golden Bridge Biotech. Co. Ltd., ZB-
2301), finally washed with PBST and PBS successively
for 5 min by 3 times. The gel film images was deve-
loped in A-B mixed developing agent and scanned with
Bio-Rad-2000 gel-imaging system to analysed gray value
of strap by Quantity One software. In the same specimen,
the gray value of β-action (42 kD), as an internal para-
meter, was also detected to calibrate the content of each
target protein. The relative content of protein (RCP) = the
gray value of MBP/the gray value β-action. The experi-
ment was repeated 3 times and the results presented with
mean ± standard deviation.
Reverse transcription polymerase chain reaction (RT-PCR)
Extraction of total RNA: Chose 5 rats from control
group and model group respectively and (16 × 3) rats in
treatment group randomly and anesthetized by chloral
hydrate after treatment 24 h. Took 200 mg ischemic
brain tissue and put into 1.5 ml EP tube. Added RNA-
Solv reagent 1 ml, minced and grinded, oscillated ultra-
sonically for 30 s and placed 5 min at room temperature,
and centrifuged (4°C 12,000 g) for 15 min. Took the
supernatant into another EP tube and added chloroform
0.2 ml, shocked and mixed 15 s, placed on ice for
10 min and centrifuged (4°C 12,000 g) for 15 min. Then,
collected supernatant into another EP tube and join iso-
propyl alcohol 0.5 ml, blended gently, then placed on
the ice for 10 min, centrifuged (4°C 12,000 g) for 15 min
and discarded supernatant. Washed precipitation using
1 ml 75% alcohol, mixed and centrifuged (4°C 7,500 g)
for 5 min, then abandoned supernatant carefully, dried
30 min (precipitation changed from white to transparent)
in fume hood, and put in 57°C water bath for 10 min after
adding 0.1% DEPC-H2O 30 μl. The purity and abundance
of RNA were determined by ultraviolet spectrophotometer
(Bekamann DU640, USA) and stored at −20°C.
RT-PCR: (1) Primers were designed with Premier 5.0
software and synthesized by Shanghai Invitrogen Co.
Ltd. Target gene NSE (103 bp), sense primer: 5'–CCC
ATT GGT GCA CAC TAA CCT-3', antisense: 5'-CGA
CTT GAT TCA GCG ACA GGA-3'; GAPDH (110 bp)
as an internal parameter, sense primer: 5'-CGT TGA
CAT CCG TAA AGA CCT C-3', antisense: 5'-TAGGAG CCA GGG CAG TAA TCT-3'. (2) Reverse tran-
scription synthesis system of cDNA (25 μl in total):
Oligod T 2 μl and RNA 2 μg with DEPC-H2O added to
13.4 μl, and the mixed liquid was placed at 70°C for
5 min, then ice-bath for 5 min. Plused M-MLV RT 5 ×
5 μl, dNTP mixture 5 μl, RNase inhibitor 0.62 μl and
M-MLV RTase 1 μl. Then the mixed liquid was placed at
42°C for 1 h, reacted at 70°C for 15 min, and finally pre-
served at −20°C. (3) PCR system (50 μl): 5 μl 10 × PCR
buffer, 1 μl dNTP (10 mmol/L), 1 μl cDNA, 1 μl primer1
(10 um), 1 μl primer2 (10 um), 0.4 μl Taq polymerase,
with 0.1% DEPC-H2O added to 50 μl. PCR condition: The
cDNA of MBP and GAPDH were amplified for 30 cycles,
at 95°C for 3 min, 94°C for 30 s, 58°C for 30 s, and 72°C
for 40 s, and finally extension at 72°C for 3 min. (4) Elec-
trophoresis: 50 μl RT-PCR system with 10 μl 6 × DNA
loading buffer added into, was shocked and blended, and
then centrifuged for 5 s, followed with 10 μl sample
loaded. Appropriate DNA Marker was selected to load
2 μl, and followed with 2% agarose gel electrophoresis
(120 V/100 mA) for 30 min and ethidium bromide (EB)
staining. Quantity One software was used to analyse the
gray value after scanning by Bio-Rad-2000 gel-imaging
system. The results were presented as relative abundance
of mRNA (RAM): the gray values of MBP mRNA/
GAPDH mRNA. The results were repeated 3 times and
expressed with mean ± standard deviation.
Statistical analysis
Determination of statistical significance was carried out
with Student’s t-test between two groups. One-way analysis
of variance (One-way ANOVA) was used for the compari-
son of multiple sets of data, then further study was made
by Least significant differences (LSD) to compare multiple
data. All datum statistically analysed by SPSS 17.0 software.
Values were considered to be significant when P was less
than 0.05.
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